Lv61
2876 积分 2021-08-27 加入
An operational perturbation proteomics-based virtual cell model
4小时前
已完结
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
18天前
已完结
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology
18天前
已完结
Abstract 7260: Predicting the starting dose and step-up regimen for first-in-human trial of T-cell engagers using mechanistic mathematical modeling
18天前
已完结
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients
18天前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
18天前
已完结
Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids
18天前
已完结
Human organoids with an autologous tissue-resident immune compartment
18天前
已完结
Species differences influencing the safety assessment of CD3 T-cell engagers
18天前
已完结
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy
18天前
已完结
皖公网安备34019202002308
